2018
National determinants of active surveillance among patients with clinical stage 1A kidney tumors.
Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.Peer-Reviewed Original ResearchSmall renal massesNational Cancer DatabaseActive surveillanceInitial managementRenal massesCancer DatabaseClinical T1a renal massesMultivariate logistic regression modelFacility-level differencesWest North Central census divisionCancer registry dataT1a renal massesLogistic regression modelsSocio-demographic determinantsDefinitive therapyDefinitive treatmentPatient ageTotal cohortPractice patternsNational utilizationRegistry dataInclusion criteriaCaucasian raceKidney tumorsPatients
2015
Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy.
Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.Peer-Reviewed Original ResearchCAPRA scoreActive surveillanceProstate cancerAdverse pathologyBiopsy GleasonProstate cancer active surveillanceIntermediate-risk prostate cancerProstate Risk Assessment (CAPRA) scoreRisk categoriesMultivariate logistic regression modelAdverse surgical pathologyRisk prostate cancerAdverse pathological outcomesRisk assessment scoreLogistic regression modelsBiopsy upgradeGleason upgradeSurveillance biopsiesMedian ageRepeat biopsyInitial diagnosisSubsequent biopsyRadical prostatectomyMedian changeSurgical pathology